Amgen Inc. (AMGN:NASDAQ) closed at $439.26 on October 23, 2026, down 1.79% on the day. The stock trades 2.6% below its 52-week high of $450.98 and 52.5% above its 52-week low of $288.00. Over the past year, it gained 50.6%. Amgen Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 23, 2025, AMGN closed higher on 131 days (52%). Its best day was February 4, 2026 (+8.15%) and its worst was September 8, 2026 (-10.08%). The stock moved 10% or more in a single session 1 time.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for the prevention of skeletal-related events; Repatha to treat coronary artery diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Erenumab for the prevention of chronic migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; AMJEVITA to treat psoriatic arthritis and polyarticular juvenile idiopathic arthritis, as well as ankylosing spondylitis and moderate-to-severe rheumatoid arthritis; ABP 215 for biosimilar candidates; and ABP 980 to treat human...
Find more stocks like AMGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.